ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 3, 2017
Dividend Increases/Decreases for the Week Ending June 30
Let's take a look at companies raising/lowering their dividends this week.
Jul 2, 2017
Prepared Remarks From Nelson Exclusive Conference Call June 30
Read President of Investment Research Brian Nelson's prepared remarks for the yearly roundup conference call, held for Nelson Exclusive members.
Jul 1, 2017
Valuentum's July Edition of Its Dividend Growth Newsletter
Image Source: Chris Potter. The link to download the July edition of the Dividend Growth Newsletter can be found in this article.
Jul 1, 2017
Malkiel Balks, Yellen Talks
Let’s first address how research in the financial industry is becoming more and more open to combining value and momentum considerations. We’ll also cover a few takeaways from the stress tests and some ‘strong’ talk from Fed Chair Janet Yellen.
Jul 1, 2017
The Financially-Healthiest Dividend Payers Yielding Over 2%
We multiply each firm’s dividend yield by its Dividend Cushion ratio to get this coveted list of the financially-healthiest dividend payers yielding over 2%. Use the download in this article to develop this screen.
Jun 30, 2017
The Biosimilar Revolution Remains Stymied
Image Source: Express ScriptsWe remain intrigued by the potential of the upcoming wave of biosimilar versions of well-established specialty drugs. Even though we have been disappointed by recent FDA decisions, we feel it is inevitable biosimilars will enter the market. Let’s update readers on our thoughts.
Jun 29, 2017
Novartis Is Building a Significant Cardiovascular Franchise
Image shown: The performance of Novartis since the beginning of 2014.One of the more interest times to consider speculating in the biotech/pharmaceutical space is in advance of the identification of the full potential of the clinical pipeline. Once investors recognize the full “value” of an entity’s pipeline, they often bid the company’s equity price higher well in advance of what traditional near-term fundamental metrics might indicate. The results recently released by Novartis have significantly solidified its clinical pipeline, in our view. Let’s take a look.
Jun 28, 2017
Incyte, Examining Epacadosat's Recent Data
Image shown: Incyte's stock price performance since the beginning of 2014.The need for innovative advances in oncology remains unmet in spite of the entrance of next-generation treatments. We will examine the recent data release from Incyte pertaining to its novel treatment Epacadosat. Incyte hopes it will boost response rates which will greatly expand the number of patients that can be effectively treated. Let’s examine the details of the data release.
Jun 27, 2017
Do You Know What You Don't Know?
Find out what you may have missed with a short excerpt by speaker Brian Nelson from part III of Valuentum's four-part investment education workshop. You may be surprised!
Jun 26, 2017
Random Musings: Retail, REITs, BlackBerry, and More
Image shown: Best Buy's resiliency in the face of competition from Amazon. Let’s cover some recent news.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.